Xu Z - Search Results

1

Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020.

Wei Y, Zhang Y, Xu Z, Wang G, Zhou Y, Li H, Shi L, Naci H, Wagner AK, Guan X. Wei Y, et al. Among authors: xu z. Lancet Reg Health West Pac. 2024 Apr 2;45:101055. doi: 10.1016/j.lanwpc.2024.101055. eCollection 2024 Apr. Lancet Reg Health West Pac. 2024. PMID: 38590780 Free PMC article.

2

Differences of healthcare utilization and cost between cancer inpatients with and without depression: Based on national health insurance database.

Bai L, Huang C, Xu Z, Huang T, Guan X, Shi L. Bai L, et al. Among authors: xu z. Psychooncology. 2021 Jun;30(6):979-981. doi: 10.1002/pon.5660. Epub 2021 Mar 5. Psychooncology. 2021. PMID: 33624375 No abstract available.

3

Acid Suppression Use Among Infants in One Tertiary Children's Hospital in China, 2015-2018: A Retrospective Observational Study.

Zhou Y, Xu L, Wushouer H, Yu A, Xu Z, Chen C, Cui Y, Lu Q, Guan X, Shi L. Zhou Y, et al. Among authors: xu l, xu z. Front Pediatr. 2021 May 21;9:679203. doi: 10.3389/fped.2021.679203. eCollection 2021. Front Pediatr. 2021. PMID: 34095037 Free PMC article.

4

Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs.

Naci H, Guan X, Woloshin S, Xu Z, Wagner AK. Naci H, et al. Among authors: xu z. JAMA Intern Med. 2021 Nov 1;181(11):1521-1522. doi: 10.1001/jamainternmed.2021.3505. JAMA Intern Med. 2021. PMID: 34251420 Free PMC article.

5

Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database.

Bai L, Xu Z, Huang C, Sui Y, Guan X, Shi L. Bai L, et al. Among authors: xu z. Lancet Reg Health West Pac. 2020 Nov 20;5:100060. doi: 10.1016/j.lanwpc.2020.100060. eCollection 2020 Dec. Lancet Reg Health West Pac. 2020. PMID: 34327398 Free PMC article.

6

Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.

Fu M, Naci H, Booth CM, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner AK. Fu M, et al. Among authors: xu z. JAMA Intern Med. 2021 Dec 1;181(12):1596-1604. doi: 10.1001/jamainternmed.2021.5983. JAMA Intern Med. 2021. PMID: 34661604 Free PMC article.

7

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.

Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X. Zhang Y, et al. Among authors: xu z. JAMA Netw Open. 2022 Aug 1;5(8):e2225973. doi: 10.1001/jamanetworkopen.2022.25973. JAMA Netw Open. 2022. PMID: 35947385 Free PMC article.

8

Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.

Naci H, Zhang Y, Woloshin S, Guan X, Xu Z, Wagner AK. Naci H, et al. Among authors: xu z. Lancet Oncol. 2024 Jun;25(6):760-769. doi: 10.1016/S1470-2045(24)00152-9. Epub 2024 May 13. Lancet Oncol. 2024. PMID: 38754451 Free article.

9

Valence Electron: A Descriptor of Spinel Sulfides for Sulfur Reduction Catalysis.

Shen Z, Song P, Xie W, Tannesia L, Tang K, Sun Y, Xi S, Xu ZJ. Shen Z, et al. Among authors: xu zj. Adv Mater. 2025 Jan 10:e2418090. doi: 10.1002/adma.202418090. Online ahead of print. Adv Mater. 2025. PMID: 39791291

10

Beyond the Surface: Tracing the Evolution of Inflammatory Mechanism in Depression through Bibliometric Analysis.

Xu ZY, Zhang T, Gong H, Zheng H, Liu MS, Guo BH, Wang YX, Su WJ. Xu ZY, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 8. doi: 10.2174/0118715303325541241024060229. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38,999 results

Search Page

Filters